# Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter

> **NCT02035046** · NA · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 250 (estimated)

## Conditions studied

- Heterozygous Carriers of Gitelman Syndrome

## Interventions

- **PROCEDURE:** Samplings of blood
- **PROCEDURE:** Sampling of urine
- **PROCEDURE:** Measure of the blood pressure
- **PROCEDURE:** glycemia test

## Key facts

- **NCT ID:** NCT02035046
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2017-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035046, "Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02035046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*